Description: 4basebio PLC engages in the research, development, manufacturing, and commercialization of synthetic DNA and RNA products, and targeted non-viral vector solutions in the United States, Europe, and internationally. The company offers AVV and Lentivirus manufacturing services for use in gene therapies and vaccines. It also offers access to its targeted non-viral delivery platform, Hermes. The company was formerly known as 4basebio UK Societas and changed its name to 4basebio PLC in July 2021. 4basebio PLC was founded in 2008 and is based in Cambridge, the United Kingdom.
Home Page: www.4basebio.com
4BB Technical Analysis
25 Norman Way
Cambridge,
CB24 5QE
United Kingdom
Phone:
44 1223 967 943
Officers
| Name | Title |
|---|---|
| Dr. Heikki Lanckriet Ph.D. | CEO, Chief Scientific Officer & Executive Director |
| Mr. David Roth | CFO, Company Secretary & Executive Director |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.8284 |
| Price-to-Sales TTM: | 337.5943 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 101 |